Suzhou Zelgen Biopharmaceuticals Co (SHSE:688266) 5-Year RORE % : -148.60% (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SHSE:688266 Suzhou Zelgen Biopharmaceuticals Co Ltd SHSE:688266
70 GF Score
Price ¥120.40
GF Value ¥221.44
Valuation Significantly Undervalued
! 4 Warning Signs
View Full Analysis

What is Suzhou Zelgen Biopharmaceuticals Co 5-Year RORE %?

Suzhou Zelgen Biopharmaceuticals Co SHSE:688266 +0.15% 70 5-Year RORE % is -148.60 as of Jun. 2026. GuruFocus rates SHSE:688266 with a GF Score™ of 70/100 and a GF Value™ of ¥221.44 (Significantly Undervalued). The stock has 4 warning signs investors should review. Among 1,139 Biotechnology companies, Suzhou Zelgen Biopharmaceuticals Co ranks worse than 96.93% on this metric.

Return on Retained Earnings (RORE) is an indicator of a company's growth potential, it shows how much a company earns by reinvesting its retained earnings, i.e. profits after dividend payments. Suzhou Zelgen Biopharmaceuticals Co's 5-Year RORE % for the quarter that ended in Jun. 2026 was -148.60%.

The industry rank for Suzhou Zelgen Biopharmaceuticals Co's 5-Year RORE % or its related term are showing as below:

SHSE:688266's 5-Year RORE % is ranked worse than
96.93% of 1139 companies
in the Biotechnology industry
Industry Median: -10.54 vs SHSE:688266: -148.60

Suzhou Zelgen Biopharmaceuticals Co  (SHSE:688266) 5-Year RORE % Explanation

Return on Retained Earnings (RORE) is important to investors because it reveals a company's efficiency and growth potential. A higher RORE indicates a higher return. A high RORE indicates that the company should reinvest profits into the business. A lower RORE suggests that the company should distribute profits to shareholders by paying out dividends, since those dollars aren't generating much additional growth for the company.

There are a several different ways to arrive at the Return on Retained Earnings. The simplest way to calculate it is by using published information on Earnings per Share (EPS) and Dividend per Share (DPS) over a selected period. Here, 5-year period is chosen.

Be Aware

Please keep in mind that the RORE is relative to the nature of the business and its competitors. If another company in the same sector is producing a lower return on retained earnings, it doesn’t necessarily mean it’s a bad investment. It may just suggest the company is older and no longer in a high growth stage. At such a stage in the business cycle, it would be expected to see a lower RORE and higher dividend payout.


Suzhou Zelgen Biopharmaceuticals Co 5-Year RORE % Related Terms


Suzhou Zelgen Biopharmaceuticals Co 5-Year RORE % Historical Data

* Premium members only.

The historical data trend for Suzhou Zelgen Biopharmaceuticals Co's 5-Year RORE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Suzhou Zelgen Biopharmaceuticals Co 5-Year RORE % Chart

Suzhou Zelgen Biopharmaceuticals Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
5-Year RORE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 -17.22 -9.89 -20.93

Suzhou Zelgen Biopharmaceuticals Co Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
5-Year RORE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -12.72 -17.94 -20.93 -119.09 -148.60

SHSE:688266 vs VRTX, REGN, RVMD: 5-Year RORE % Comparison

For the Biotechnology subindustry, Suzhou Zelgen Biopharmaceuticals Co's 5-Year RORE %, along with its competitors' market caps and 5-Year RORE % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Suzhou Zelgen Biopharmaceuticals Co 5-Year RORE % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Suzhou Zelgen Biopharmaceuticals Co's 5-Year RORE % distribution charts can be found below:

* The bar in red indicates where Suzhou Zelgen Biopharmaceuticals Co's 5-Year RORE % falls into.


SHSE:688266
70GF Score
Suzhou Zelgen Biopharmaceuticals Co Ltd SHSE:688266
5-Year RORE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Suzhou Zelgen Biopharmaceuticals Co 5-Year RORE % Calculation

Suzhou Zelgen Biopharmaceuticals Co's 5-Year RORE % for the quarter that ended in Jun. 2026 is calculated as:

5-Year RORE %=( Most Recent EPS (Diluted)- First Period EPS (Diluted) )/( Cumulative EPS (Diluted) for 5-year -Cumulative Dividends per Share for 5-year )
=( 2.08--2.17 )/( -2.86-0 )
=4.25/-2.86
=-148.60 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of 5-Year RORE %, the most recent and first period EPS (Diluted) is the trailing twelve months (TTM) data ended in Jun. 2026 and 5-year before.

Frequently Asked Questions Learn more about 5-Year RORE % →
What does a 5-Year RORE % of -148.60 mean?
Suzhou Zelgen Biopharmaceuticals Co (SHSE:688266) has a 5-Year RORE % of -148.60 as of Jun. 2026. 5-Year RORE % shows how much a company earns by reinvesting its retained earnings in 5-year. View historical data on Suzhou Zelgen Biopharmaceuticals Co and its competitors. According to the industry distribution chart, Suzhou Zelgen Biopharmaceuticals Co ranks #1104 out of 1139 companies in the Biotechnology industry, placing it in the top 96.9%.
Is Suzhou Zelgen Biopharmaceuticals Co's 5-Year RORE % too high?
Suzhou Zelgen Biopharmaceuticals Co's current 5-Year RORE % is -148.60. Based on the distribution chart, Suzhou Zelgen Biopharmaceuticals Co ranks #1104 out of 1139 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Suzhou Zelgen Biopharmaceuticals Co has a GF Score™ of 70/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Suzhou Zelgen Biopharmaceuticals Co's 5-Year RORE % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Suzhou Zelgen Biopharmaceuticals Co ranks #1104 out of 1139 companies for 5-Year RORE %. This places Suzhou Zelgen Biopharmaceuticals Co in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year RORE % for a Biotechnology company?
A good 5-Year RORE % depends on the Biotechnology industry context. However, 5-Year RORE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year RORE % mean?
A high 5-Year RORE % can signal that a stock is expensive relative to its fundamentals. 5-Year RORE % shows how much a company earns by reinvesting its retained earnings in 5-year. View historical data on Suzhou Zelgen Biopharmaceuticals Co and its competitors. Suzhou Zelgen Biopharmaceuticals Co's current 5-Year RORE % is -148.60. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Suzhou Zelgen Biopharmaceuticals Co stock overvalued right now?
Based on GuruFocus' analysis, Suzhou Zelgen Biopharmaceuticals Co (SHSE:688266) is currently considered Significantly Undervalued. The stock's GF Value™ is ¥221.44, compared to a current price of ¥120.40 — trading 45.6% below its estimated fair value. The current 5-Year RORE % is -148.60. Suzhou Zelgen Biopharmaceuticals Co's overall GF Score™ is 70/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year RORE % calculated?
5-Year RORE % is calculated from a company's financial statements. For Suzhou Zelgen Biopharmaceuticals Co (SHSE:688266), the current 5-Year RORE % is -148.60 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Suzhou Zelgen Biopharmaceuticals Co (SHSE:688266) Overvalued in 2026?

Based on GuruFocus' analysis, Suzhou Zelgen Biopharmaceuticals Co stock appears to be undervalued. The current stock price of ¥120.40 is trading 45.6% below its estimated GF Value™ of ¥221.44. GuruFocus considers Suzhou Zelgen Biopharmaceuticals Co to be Significantly Undervalued.

Key valuation signals for SHSE:688266:

  • 5-Year RORE %: -148.60
  • GF Value™: ¥221.44 vs. price of ¥120.40 (45.6% below fair value)
  • GF Score™: 70/100 with 4 warning signs

No single metric tells the full story. See the SHSE:688266 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Suzhou Zelgen Biopharmaceuticals Co Business Description

Address No.209 Chenfeng Road, Yushan Town, Jiangsu Province, Kunshan, CHN
Suzhou Zelgen Biopharmaceuticals Co Ltd is engaged in research and development of new chemical and biological drugs for various therapeutic areas, including tumors, bleeding and blood diseases, and hepatobiliary diseases.
70GF Score

Get the complete analysis for SHSE:688266

5-Year RORE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

¥120.40
Price
¥221.44
GF Value